In one aspect, a system for detecting inflammation is disclosed, which includes at least one sensor comprising at least one port for receiving a biological sample, and at least one electrochemical cell in fluid communication with said at least one port for receiving said biological sample, said electrochemical cell comprising at least two electrically conductive electrodes, where at least one of said electrodes is functionalized with at least one probe exhibiting specific binding to at least one inflammation biomarker. The system may further include a circuitry for detecting a redox current flowing through said at least one electrode and/or an electrical impedance across said electrodes in response to interaction of the functionalized electrode with the sample, and generating signals in response to said detection. By way of example, the biological sample can be a subject's blood serum.

Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

Methods and systems for capture object-based assays, including for determining a measure of the concentration of an analyte molecule or particle in a fluid sample, are described. The methods and systems may relate to high sensitivity detection of analytes, sometimes using assay conditions and sample handling that result in the capture and detection of a high percentage of the analyte molecules or particles in a fluid sample using relatively few capture objects. Apparatuses and methods for immobilizing capture objects with respect to assay sites, in some instances with unexpectedly high efficiencies are also described. Some such apparatuses involve the use of force fields and fluid meniscus forces, alone or in combination, to facilitate or improve capture object immobilization. Also described are techniques for utilizing a relatively high percentage of capture objects in an assay sample, such as by using disclosed sample washing techniques, imaging systems, and analysis procedures that can reduce capture object loss.

Methods and devices to identify contact lens wearers predisposed to contact lens discomfort are described. The methods and devices involve obtaining a tear film sample from a person and determining an amount of interleukin-17A present in the tear film sample.

The present invention discloses a pencil-like optical fiber sensor probe, including an inner tube, a light screening casing, a clamping device, an optical fiber and an optical probe; a portable immunosensor, including the pencil-like optical fiber sensor probe, an immersion immune response reagent strip, a touch-screen computer, a compact battery-powered sensitive photon counting detector and a case; and a use of the immunosens in detecting inflammatory markers. The design of the pencil-like optical sensor probe greatly simplifies the immune analysis process by combining the immersion immune response reagent strip. Each optical probe allows for up to 10 immunoassays, which reduces the experimental cost and avoids frequent replacement of the probe. The integrated detecting system is powered by battery which is suitable for in-situ analysis and detection. The sensor also has a high stability and sensitivity.

The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.

Disclosed are methods of isolating a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; selecting the autologous T cells; and isolating a nucleotide sequence that encodes the TCR from the selected autologous T cells, wherein the TCR has antigenic specificity for the mutated amino acid sequence encoded by the cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.

A method for quantifying a plurality of target molecules in a sample may include releasing a target molecule from a non-covalent bond of a conjugate by using a fusion molecule. A kit may include a detection conjugate, a release reagent, nucleic acid amplification agents, and an amplification detection probe. A device may be designed to perform the methods.